Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...
Deals
Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...
Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...
AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...
TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices
TÜV Rheinland Greater China and United Imaging Healthcare Co., LTD have signed a strategic cooperation...
ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced that the first patient has been dosed in...
Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
Takeda Pharmaceutical Company Limited China (TYO: 4502; NYSE: TAK) entered into a partnership agreement with...
Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has signed an exclusive licensing...
Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
Mirxes Holding Company Limited (HKG: 2629) announced that its clinical diagnostic laboratory, M Diagnostics Philippines...
METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
METiS TechBio (HKG: 7666) and WestVac Biopharma, an innovative vaccine and immunotherapy company led by...
Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review
Simcere Pharmaceutical Group Limited (HKG: 2096) announced a strategic collaboration with Reyoung (Suzhou) Biology Science...
VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
VectorBuilder and Lir Therapeutics announced a strategic collaboration to integrate their respective technological strengths in...
LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision
LEO Pharma A/S announced that it has entered into an agreement with Tanabe Pharmaceutical to...
Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306
Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia‑headquartered Avalon Pharma announced the expansion of their...
OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
OmniAb, Inc. (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly (NYSE:...
Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
Navi Therapeutics (Shanghai) Co., Ltd. announced the successful completion of two financing rounds — Angel...
Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform
Ledeinno Medical Valley announced the completion of its Series B+ and Series B++ funding rounds...
Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials
Enginprime Medical announced the completion of its Series A funding round of nearly 100 million...
Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has entered into a strategic collaboration...